Guild Investment Management’s Monty Guild and team don’t think it’s time to start buying biotech stocks just yet but urge investors to “get their buy lists ready.” That starts with companies like Coherus Biosciences (CHRS), and Momenta Therapeutics (MNTA),which are poised to benefit from biosimilars, Guild says. He explains why:
It is safe to say that the verdict is in: the political pressure is not coming off healthcare.
